Home > Dermatology > AAD 2018 > Late-breakers > Dual JAK/SYK inhibitor and anti-IL-33 blockade

Dual JAK/SYK inhibitor and anti-IL-33 blockade

Presented By
Dr Robert Bissonnette, Innovaderm Research, Canada; Prof. Graham Ogg, Oxford University, United Kingdom
AAD 2018
First promising data for a dual JAK/SYK inhibitor “This is the first clinical study with ASN002, a novel JAK/SYK inhibitor” said Dr Robert Bissonnette of Innovaderm Research at the presentation of this Phase 1b trial [3]. According to Dr Bissonnette, ASN002 is an interesting molecule and somewhat different from other JAK inhibitors, because it also affects spleen tyrosine kinase (SYK). This intracellular kinase inhibits IL-17 signalling/CC chemokine ligand 20 production in keratinocytes, increases terminal differentiation of keratinocytes, and inhibits B-cell signalling, which plays a role in skin immunity. AS002 thus diminishes production of Th2 and Th22 cytokines. The dysregulation of Th2 and Th22 cytokine pathways are a hallmark of the pathogenesis of AD. Although safety was the primary target of this trial there were also several efficacy targets. The 36 study participants represented the typical AD population with moderate-to-severe dise...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on